Thermal ablation compared to stereotactic body radiation therapy for hepatocellular carcinoma: A multicenter retrospective comparative study
Authors:
- Andrew M. MoonAMAndrew M. Moon
- Hannah P. KimHKHannah P. Kim
- Amit G. SingalASAmit G. Singal
- Dawn OwenDODawn Owen
- Mishal Mendiratta-LalaMMMishal Mendiratta-Lala
- Neehar D. ParikhNPNeehar D. Parikh
- Steven C. RoseSRSteven C. Rose
- Katrina A. McGintyKMKatrina A. McGinty
- Chris B. AgalaCAChris B. Agala
- Lauren M. BurkeLBLauren M. Burke
- Anjelica AbateAAAnjelica Abate
- Ersan AltunEAErsan Altun
Open Access
- 14 June 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 7 (7)
Abstract
Background & Aims: Early-stage HCC can be treated with thermal ablation or stereotactic body radiation therapy (SBRT). We retrospectively compared local progression, mortality, and toxicity among patients with HCC treated with ablation or SBRT in a multicenter, US cohort. Approach & Results: We included adult patients with treatment-naïve HCC lesions without vascular invasion treated with thermal ablation or SBRT per individual physician or institutional preference from January 2012 to December 2018. Outcomes included local progression after a 3-month landmark period assessed at the lesion level and overall survival at the patient level. Inverse probability of treatment weighting was used to account for imbalances in treatment groups. The Cox proportional hazard modeling was used to compare progression and overall survival, and logistic regression was used for toxicity. There were 642 patients with 786 lesions (median size: 2.1 cm) treated with ablation or SBRT. In adjusted analyses, SBRT was associated with a reduced risk of local progression compared to ablation (aHR 0.30, 95% CI: 0.15–0.60). However, SBRT-treated patients had an increased risk of liver dysfunction at 3 months (absolute difference 5.5%, aOR 2.31, 95% CI: 1.13–4.73) and death (aHR 2.04, 95% CI: 1.44–2.88, p < 0.0001). Conclusions: In this multicenter study of patients with HCC, SBRT was associated with a lower risk of local progression compared to thermal ablation but higher all-cause mortality. Survival differences may be attributable to residual confounding, patient selection, or downstream treatments. These retrospective real-world data help guide treatment decisions while demonstrating the need for a prospective clinical trial.Keywords
This publication has 33 references indexed in Scilit:
- Radiation Dose‐Volume Effects for Liver SBRTInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2021
- Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Localized Hepatocellular Carcinoma in Nonsurgically Managed Patients: Analysis of the National Cancer DatabaseJournal of Clinical Oncology, 2018
- AASLD guidelines for the treatment of hepatocellular carcinomaHepatology, 2017
- Percutaneous cooled-probe microwave versus radiofrequency ablation in early-stage hepatocellular carcinoma: a phase III randomised controlled trialGut, 2016
- Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030Journal of Clinical Oncology, 2016
- Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular CarcinomaJournal of Clinical Oncology, 2016
- Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinomaCancer, 2011
- Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinomaCancer, 2011
- Imaging Response in the Primary Index Lesion and Clinical Outcomes Following Transarterial Locoregional Therapy for Hepatocellular CarcinomaJAMA, 2010
- Modified RECIST (mRECIST) Assessment for Hepatocellular CarcinomaSeminars in Liver Disease, 2010